Compositions and methods for tumour therapy

Details Compositions and methods for tumour therapy Compositions and methods for tumour therapy

2006-06-27

2006-06-27

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C435S455000, C536S023100, C536S024500

Reexamination Certificate

active

07067495

ABSTRACT:
Compositions and methods are described that decrease or inhibit osteonectin activity in tumor cells, including cancer cells. The cells cease to be tumor-like, or become less tumor-like. Pharmaceutical composition and therapies based thereon are also described.

REFERENCES:
patent: 5248671 (1993-09-01), Smith
patent: 5340934 (1994-08-01), Termine et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5457189 (1995-10-01), Crooke et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 6030786 (2000-02-01), Cowsert
patent: 6030837 (2000-02-01), McKay et al.
patent: 6030954 (2000-02-01), Wu et al.
patent: 6031086 (2000-02-01), Switzer
patent: 6114517 (2000-09-01), Monia et al.
patent: 6117847 (2000-09-01), Bennett et al.
patent: 6117848 (2000-09-01), Monia et al.
patent: 6121047 (2000-09-01), Bennett et al.
patent: 6130088 (2000-10-01), Monia et al.
patent: 6133031 (2000-10-01), Monia et al.
patent: 6133032 (2000-10-01), Monia et al.
patent: 6136603 (2000-10-01), Dean et al.
patent: 6136604 (2000-10-01), Monia et al.
patent: 6140124 (2000-10-01), Monia et al.
patent: 6140125 (2000-10-01), Taylor et al.
patent: 6140126 (2000-10-01), Bennett et al.
patent: 6150162 (2000-11-01), Bennett et al.
patent: 6153595 (2000-11-01), Draper et al.
patent: 6156571 (2000-12-01), Bennett et al.
patent: 6159694 (2000-12-01), Karras
patent: 6159697 (2000-12-01), Monia et al.
patent: 6159734 (2000-12-01), McKay et al.
patent: 6165728 (2000-12-01), Ward et al.
patent: 6165786 (2000-12-01), Bennett et al.
patent: 6165788 (2000-12-01), Bennett et al.
patent: 6165789 (2000-12-01), Monia et al.
patent: 6165790 (2000-12-01), Borchers et al.
patent: 6165791 (2000-12-01), Popoff et al.
patent: 6168950 (2001-01-01), Monia et al.
patent: 6171860 (2001-01-01), Baker et al.
patent: 6177246 (2001-01-01), Monia et al.
patent: 6187585 (2001-02-01), Bennett et al.
patent: 6187587 (2001-02-01), Popoff et al.
patent: 6190869 (2001-02-01), Bennett et al.
patent: 6214986 (2001-04-01), Bennett et al.
patent: 6238921 (2001-05-01), Miraglia et al.
patent: WO 96/26267 (1996-08-01), None
Ledda et al. Medicina 1996; 56:51-54.
Green et al. J. of Am. Coll. Surg. vol. 191, No. 1, Jul. 2000.
Flanagan et al., Nature Biotechnology, vol. 17, No. 1, pp. 48-52, Jan. 1999.
Agrawal et al. Molecular Medicine Today, vol. 6, pp. 72-81, Feb. 2000.
Bennett et al. “Pharmacology of Antisense Therapeutic Agents”, Chapter 2, from Methods in Molecular Medicine: Antisense Therapeutics. Ed. S. Agrawal, Humana Press., Totowa, NJ, ISBN: 0—89603-305-8, 1996.
Ma et al., Biotechnology Annula Review, vol. 5, pp. 155-196, 2000.
Branch, TIBS 23, pp. 45-50, Feb. 1998.
GenEmbl database Accession No. J03040, Human SPARC/osteonectin mRNA, complete CDS, Jan. 1995.
Crooke, S. T. Vitravene—Another Piece in the mosaic. Antisense.& Nucleic Acid Drug Devel. 8 (1998), vii-viii.
Crystal, R.G. Transfer of genes to humans: Early lessons and obstacles to success. Science 270 (1995): 404-410.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisnse deliver on its promise. Proc. Natl. Acad. Sci. USA 93 (1996): 3161-3163.
Jen et al. Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies, Stem Cells 18 (2000): 307-319.
Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Orkin and Motulsky, co-chairs. National Institutes of Health (Dec. 1995).
Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Delivery Rev. 18(1996): 115-131.
Stull et al. Antigene, ribozyme,and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12(1995): 465-483.
Peracchi, A. et al. Rev. Med. Virol. vol. 14, pp. 47-64 (2004).
Crooke, S. antisense Res. and Application, Chapter 1, pp. 1-50, ed. by S. Crooke, Springer-Verlag (1998).
Branch, A. Trends in Biochem. Sci. vol. 23, pp. 45-50 (1998).
Chirila, T. et al. Biomaterials, vol. 23, pp. 321-342 (2002).
Ledda, M.F., et al., “La expresión del c-DNA antientido del gen SPARC anula la capacidad tumorigénica de células de melanoma humano,”Medicina55:565-566, Abstract No. 267, Sociedad Argentina De Investigacion Clinica (Dec. 1995).
English language translation for Ledda, M.F., et al., “The Expression of the anitsense c-DNA of the SPARC gene annuls the tumorigenic capacity of human melanoma cells,” (Dec. 1995).
Lewis, J.G., et al., “A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA,”Proc. Natl. Acad. Sci. USA 93:3176-3181, National Academy of Sciences of the USA (Apr. 1996).
Aoki, K., et al., “Liposome-mediatedin VivoGene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity,”Cancer Res. 55:3810-3816 (Sep. 1995).
Bellahcène, A., and Castronovo, V., “Increased Expression of Osteonectin and Osteopontin, Two Bone Matrix Proteins, in Human Breast Cancer,”Amer. J. Pathol. 146:95-100 (Jan. 1995).
Collier, I.E., et al., “H-ras Oncogene-transformed Human Bronchial Epithelial Cells (TBE-1) Secrete a Single Metalloprotease Capable of Degrading Basement Membrane Collagen,”J. Biol. Chem. 263:6579-6587 (May 1988).
Everitt, E.A., and Sage, E.H., “Expression of SPARC is Correlated with Altered Morphologies in Transfected F9 Embryonal Carcinoma Cells,”Exp. Cell Res. 199:134-146 (1992).
Everitt, E.A., and Sage, E.H., “Overexpression of SPARC in stably transfected F9 cells mediates attachment and spreading in Ca2+-deficient medium,”Biochem. Cell Biol. 70:1368-1379 (Dec. 1992).
Funk, S.E., and Sage, E.H., “The Ca2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells,”Proc. Natl. Acad. Sci. USA 88:2648-2652 (Apr. 1991).
Funk, S.E., and Sage, E.H., “Differential effects of SPARC and Cationic SPARC Peptides on DNA Synthesis by Endothelial Cells and Fibroblasts,”J. Cell. Physiol. 154:53-63 (Jan. 1993).
Harlow, E., and Lane, D., “Chapter 5: Immunizations,” inAntibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 53-137 (1988).
Kamihagi, K., et al., “Osteonectin/SPARC Regulates Cellular Secretion Rates of Fibronectin and Laminin Extracellular Matrix Proteins,”Biochem. Biophys. Res. Comm. 200:423-428 (Apr. 1994).
Laird, A.D., et al., “Inhibition of Tumor Growth in Liver Epithelial Cells Transfected with a Transforming Growth Factor α Antisense Gene,”Cancer Res. 54:4224-4232 (Aug. 1994).
Lane, T.F., and Sage, E.H., “Functional Mapping of SPARC: Peptides from Two Distinct Ca++-binding Sites Modulate Cell Shape,”J. Cell Biol. 111:3065-3076 (Dec. 1990).
Lane, T.F., et al., “Regulation of Gene Expression by SPARC during Angiogenesisin Vitro,” J. Biol. Chem. 267:16736-16745 (Aug. 1992).
Lane, T.F., and Sage, E.H., “The Biology of SPARC, a protein that modulates cell-matrix interactions,”FASEB J. 8:163-173 (Feb. 1994).
Lane, T.F., et al., “SPARC Is a Source of Copper-binding Peptides that Stimulate Angiogenesis,”J. Cell Biol. 125:929-943 (May 1994).
Ledda, M.F., et al., “Expression of SPARC in melanoma and dysplastic nevi,”Proceedings of the American Association for Cancer Research Annual Meeting 36:63 (1995).
Ledda, M.F., et al., “Rol del Gen SPARC en la Capacidad Tumorigenica de Celulas de Melanoma Humano,”Medicina(Buenos Aires)56:51-54 (1996)(English translation attached—Ledda, M.F., et al., “The role of SPARC gene in the tumorigenic capacity of human melanoma cells”).
Ledda, F., et al., “The Expression of the Secreted Protein Acidic and Rich in Cysteine (SPARC) Is Associated with the Neoplastic Progression of Human Melanoma,”J. Invest. Dermatol. 108:210-214 (Feb. 1997).
Ledda, M.F., et al., “Suppression of

Affiliated with

Also associated with

Rating

Compositions and methods for tumour therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for tumour therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for tumour therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3700933